medigraphic.com
ISSN 0035-0052 (Print)

2014, Number 6

<< Back Next >>

Rev Mex Pediatr 2014; 81 (6)

Contrasting two antibiotics schemes in children with septic shock spotted fever of the Rocky Mountains

Gómez RN, Fonseca CI, García ZMG, Gómez FCO, Villalobos GL

Language: Spanish
References: 21
Page: 204-208
PDF size: 135.91 Kb.


ABSTRACT

Objective: To compare two treatment guidelines to differ in handling antibiotics in patients with septic shock Spotted Fever Rocky Mountain (RMSF).
Material and methods: Design; cases and controls. We compare 2 samples at the convenience of the records of 40 patients in septic shock by RMSF treated based on a therapeutic guide that should fix septic shock considering the combination of ciprofloxacin - doxycycline, with a control group of 20 patients with RMSF treated using doxycycline plus ceftriaxone.
Results: Correction of serum lactate was achieved in 85% in the study group compared to 10% in the control group, p = 0.04. Mean arterial pressure (MAP) in the study group at 90% compared to 20% in the control group p = 0.03. Mortality and correction of platelet count there was no significant difference p = 0.23 and 0.28 respectively in 48 hours.
Conclusions: The management of septic shock by RMSF study group showed better stabilization within 48 hours.


REFERENCES

  1. Álvarez-Hernández G. Fiebre manchada de las Montañas Rocosas. Bol Clin Hosp Infant Edo Sonora. 2010; 27(2): 90-91.

  2. Lee N, Ip M, Wong B, Lui G, Yin-Tsang OT, Yiu-Lai T et al. Risk factors associated with life threatening Rickettsial infections. Am J Trop Med Hyg. 2008; 78(6): 973-978.

  3. Gómez-Rivera N, Álvarez-Hernández G, García-Zarate MG, Fonseca-Chon I, Villalobos-García L, Cano-Rangel MA. Fiebre Manchada de las Montañas Rocosas en niños. Experiencia Hospitalaria. Rev Mex Pediatr. 2013; 80(6): 227-231.

  4. Purvis JJ, Edwards MS. Doxycycline use for rickettsial disease in pediatric patients. Pediatr Infect Dis J. 2000; 19: 871-874.

  5. Breitschwerdt EB, Hegarty BC, Maggi RG et al. Rickettsia rickettsii transmission by a lone star tick, North Carolina. Emerg Infect Dis. 2011; 17(5): 873-875.

  6. Álvarez-Hernández G. La fiebre manchada de las Montañas Rocosas, una epidemia olvidada. Salud Pública Méx [online]. 2010; 52(1): 1-3. ISSN 0036-3634.

  7. Boza-Cordero R. La fiebre manchada de las Montañas Rocosas en Costa Rica, una alerta al personal de salud. Acta Médica Costarricense. 2008; 50(2): 75-76.

  8. Dellinger RP. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med. 2008; 36: 296-327.

  9. Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr. 2007; 46: 121-126.

  10. Openshaw JJ, Swerdlow DL, Krebs JW et al. Rocky Mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg. 2010; 83(1): 174-182.

  11. Dalton MJ, Clarke MJ, Holman RC et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg. 1995; 52: 405-413.

  12. Holman RC, Paddock CD, Curns AT, Krebs JW, McQuiston JH, Childs JE. Analysis of risk factors for fatal Rocky Mountain Spotted Fever: evidence for superiority of tetracyclines for therapy. J Infect Dis. 2001; 184: 1437-1444.

  13. Ren V, Hsu S. Why sulfonamides are contraindicated in Rocky Mountain spotted fever. Dermatol Online J. 2014; 18: 20 (2). pii.doi_21536.

  14. Charles R, Woods MD. Rocky Mountain Spotted fever in children. Pediatr Clin N Am. 2013; (60): 455-470.

  15. Graham J, Stockley K, Goldman RD. Tick-borne illnesses: a CME update. Pediatr Emerg Care. 2011; 27(2): 141-147; quiz 148-50.

  16. Gudiol F, Pallares R, Carratala J, Ariza F, Rulf G. Randomized Double-Blind Evaluation of Ciprofloxacin and Doxycycline for Mediterranean Spotted Fever. Antmicrobial Agents and Chemotherapy. 1989; (33): 987-88.

  17. Cunha BA. et al. Antibiotic essentials. 7th ed. Royal OaR, Mi: Physicians press, 2008, pp.442-443.

  18. Jones AE et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010; 303(8): 739-746.

  19. Dellinger RP et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med. 2013; 39(2): 165-228.

  20. Levraut J et al. Low exogenous lactate clearance as an early predictor of mortality in normolactatemic critically ill septic patients. Crit Care Med. 2003; 31(3): 705-710.

  21. John S, Bradley MD, Jackson MA. The use of systemic and topical fluoroquinolones. Pediatric. 2011; 128: 1034-1045.




2020     |     www.medigraphic.com